It’s been a while since I’ve updated my thoughts on Neurocrine Biosciences ( NBIX ), and the shares have delivered a mixed performance since then. Up about 12%, Neurocrine has done a bit better thanAnalyst’s Disclosure:I/we have a beneficial long position in the shares of NBIX either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with ...